JP2009500425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009500425A5 JP2009500425A5 JP2008520398A JP2008520398A JP2009500425A5 JP 2009500425 A5 JP2009500425 A5 JP 2009500425A5 JP 2008520398 A JP2008520398 A JP 2008520398A JP 2008520398 A JP2008520398 A JP 2008520398A JP 2009500425 A5 JP2009500425 A5 JP 2009500425A5
- Authority
- JP
- Japan
- Prior art keywords
- polymorph
- solvate
- pharmaceutically acceptable
- acceptable salt
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 22
- 239000012453 solvate Substances 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000013078 crystal Substances 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 15
- 238000000034 method Methods 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 6
- 206010012289 Dementia Diseases 0.000 claims 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- SRPXSILJHWNFMK-MEDUHNTESA-N dasotraline Chemical compound C1([C@@H]2CC[C@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-MEDUHNTESA-N 0.000 claims 4
- -1 titanium alkoxide Chemical class 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 229910015900 BF3 Inorganic materials 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 239000012024 dehydrating agents Substances 0.000 claims 2
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 claims 2
- 229960001578 eszopiclone Drugs 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000009245 menopause Effects 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000003797 solvolysis reaction Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 229910052719 titanium Inorganic materials 0.000 claims 2
- 239000010936 titanium Substances 0.000 claims 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 claims 2
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- AXXLAOYVJJFFKW-UHFFFAOYSA-N B1CCCCCCCC1C1CCCCCCCC1 Chemical group B1CCCCCCCC1C1CCCCCCCC1 AXXLAOYVJJFFKW-UHFFFAOYSA-N 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021030 Hypomania Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 208000002667 Subdural Hematoma Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 claims 1
- 229910000085 borane Inorganic materials 0.000 claims 1
- ZDQWVKDDJDIVAL-UHFFFAOYSA-N catecholborane Chemical compound C1=CC=C2O[B]OC2=C1 ZDQWVKDDJDIVAL-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 210000001652 frontal lobe Anatomy 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 150000004678 hydrides Chemical class 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims 1
- 235000019341 magnesium sulphate Nutrition 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002808 molecular sieve Substances 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- AKEYUWUEAXIBTF-UHFFFAOYSA-N n-methylnaphthalen-1-amine Chemical compound C1=CC=C2C(NC)=CC=CC2=C1 AKEYUWUEAXIBTF-UHFFFAOYSA-N 0.000 claims 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims 1
- 239000012279 sodium borohydride Substances 0.000 claims 1
- 229910000033 sodium borohydride Inorganic materials 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical group [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69701305P | 2005-07-06 | 2005-07-06 | |
| PCT/US2006/026361 WO2007006003A2 (en) | 2005-07-06 | 2006-07-06 | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009500425A JP2009500425A (ja) | 2009-01-08 |
| JP2009500425A5 true JP2009500425A5 (enExample) | 2009-08-20 |
Family
ID=37605221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008520398A Pending JP2009500425A (ja) | 2005-07-06 | 2006-07-06 | エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20080293726A1 (enExample) |
| EP (2) | EP1904066B1 (enExample) |
| JP (1) | JP2009500425A (enExample) |
| CN (1) | CN101553217A (enExample) |
| AU (1) | AU2006264317B2 (enExample) |
| CA (2) | CA2614282A1 (enExample) |
| MX (1) | MX2008000250A (enExample) |
| WO (1) | WO2007006003A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| PT1691811E (pt) * | 2003-12-11 | 2014-10-30 | Sunovion Pharmaceuticals Inc | Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão |
| ATE454140T1 (de) | 2004-02-18 | 2010-01-15 | Sepracor Inc | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität |
| WO2007006003A2 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| DK2816024T3 (en) * | 2006-03-31 | 2017-10-30 | Sunovion Pharmaceuticals Inc | CHIRALE AMINER |
| WO2009085972A1 (en) * | 2007-12-19 | 2009-07-09 | Sepracor Inc. | Maleate, besylate, and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine |
| US8198277B2 (en) | 2007-12-19 | 2012-06-12 | Sunovion Pharmaceuticals Inc. | L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine |
| US8269005B2 (en) * | 2007-12-19 | 2012-09-18 | Sunovion Pharmaceuticals Inc. | L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine |
| US8198278B2 (en) | 2007-12-19 | 2012-06-12 | Sunovion Pharmaceuticals Inc. | Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine |
| US8212036B2 (en) | 2007-12-19 | 2012-07-03 | Sunovion Pharmaceuticals Inc. | Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine |
| US20110053945A1 (en) * | 2007-12-19 | 2011-03-03 | Sepracor Inc. | Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihy-dro-5h-pyrrolo[3,4-b]pyrazine |
| US8268832B2 (en) * | 2007-12-19 | 2012-09-18 | Sunovion Pharmaceuticals Inc. | Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine |
| AU2010208240A1 (en) | 2009-01-30 | 2011-09-22 | Sunovion Pharmaceuticals Inc | Coated tablets of 6-(5-chloro-2-pyridyl) -5-[ (4-methyl-1-piperazinyl) carbonyloxy]-7-oxo-6, 7-dihydro-5H-pyrrol o [3,4-b] pyrazine and methods for measuring effectiveness of coating |
| EP2429514A1 (en) * | 2009-05-13 | 2012-03-21 | Sunovion Pharmaceuticals Inc. | Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof |
| RU2578956C2 (ru) * | 2009-12-04 | 2016-03-27 | Суновион Фармасьютикалз Инк. | Лекарственные формы, соли и полиморфы транснорсертралина и их применение |
| KR101340270B1 (ko) * | 2011-11-10 | 2013-12-10 | 보령제약 주식회사 | (+)-시스-서트랄린의 선택적인 제조방법 |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| CN104922687A (zh) * | 2015-04-21 | 2015-09-23 | 襄阳市中心医院 | 一种右佐匹克隆-环糊精包合物及其制备方法 |
| JP2022532638A (ja) * | 2019-05-13 | 2022-07-15 | バステラ カンパニー リミテッド | オートファジー活性を通じた退行性脳疾患の予防または治療用薬学的組成物 |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1124485B (de) | 1960-02-12 | 1962-03-01 | Hoechst Ag | Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen |
| OA04285A (fr) | 1972-01-07 | 1979-12-31 | Rhone Poulenc Sa | Nouveaux dérivés de la pyrrolo (3,4-b) pyrazine et leur préparation. |
| US4045488A (en) | 1974-11-06 | 1977-08-30 | Pfizer Inc. | Aminophenyltetralin compounds |
| AR208414A1 (es) | 1974-11-07 | 1976-12-27 | Rhone Poulenc Ind | Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2) |
| DE2963572D1 (en) | 1978-04-11 | 1982-10-21 | Ciba Geigy Ag | Mercapto-imidazole derivatives, their preparation, mercapto-imidazole derivatives for the treatment of inflammatory diseases and their pharmaceutical compositions |
| US4556676A (en) | 1979-11-01 | 1985-12-03 | Pfizer Inc. | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| ZA817261B (en) | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
| SE8203624L (sv) | 1981-06-15 | 1982-12-16 | Yung Hee Kim | Forvermningsanordning for oljebrennare |
| US4540690A (en) | 1982-02-09 | 1985-09-10 | The Upjohn Company | 2-(Phenylmethylene)cycloalkylamines and -azetidines |
| DE3431541A1 (de) | 1984-08-28 | 1986-03-06 | Hoechst Ag, 6230 Frankfurt | Cis,endo-2-azabicycloalkan-3-carbonsaeure-derivate, verfahren zu deren herstellung, deren verwendung sowie zwischenprodukte bei deren herstellung |
| US4738709A (en) | 1985-01-10 | 1988-04-19 | Ppg Industries, Inc. | Herbicidally active substituted benzisoxazoles |
| US4634703A (en) | 1985-10-25 | 1987-01-06 | Bristol-Myers Company | Method for alleviation of panic disorders |
| US4687772A (en) | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
| US4751231A (en) | 1987-09-16 | 1988-06-14 | Merck & Co., Inc. | Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents |
| US5468749A (en) | 1988-08-30 | 1995-11-21 | Gawin; Frank H. | Method for treatment of substance addiction |
| US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
| JP2785879B2 (ja) | 1989-05-31 | 1998-08-13 | ジ・アップジョン・カンパニー | 治療学的に有用な２―アミノテトラリン誘導体 |
| IL97054A (en) | 1990-02-12 | 1995-10-31 | Bristol Meyers Squibb Co | Pharmaceutical preparations containing bospirone for the treatment of coma |
| US5086054A (en) | 1990-07-31 | 1992-02-04 | Sri International | Novel arylcycloalkanepolyalkylamines |
| FR2671800B1 (fr) * | 1991-01-17 | 1993-03-12 | Rhone Poulenc Rorer Sa | Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent. |
| JPH04327532A (ja) | 1991-01-31 | 1992-11-17 | Bristol Myers Squibb Co | 活動過剰を伴う注意力欠乏疾患の治療に使用する医薬製剤 |
| US5786357A (en) * | 1991-12-02 | 1998-07-28 | Sepracor Inc. | Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone |
| US5858407A (en) | 1992-02-27 | 1999-01-12 | Alza Corporation | Method for administering tandospirone |
| GB9208492D0 (en) | 1992-04-16 | 1992-06-03 | Glaxo Spa | Heterocyclic compounds |
| CA2146755A1 (en) | 1992-10-28 | 1994-05-11 | Kenji Takeda | Novel 1,2-benzoisoxazole derivative or its salt and brain-protecting agent comprising the same |
| GB9304500D0 (en) | 1993-03-05 | 1993-04-21 | Glaxo Spa | Heterocyclic compounds |
| ES2081747B1 (es) | 1993-09-07 | 1997-01-16 | Esteve Labor Dr | Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos. |
| GB9321221D0 (en) | 1993-10-14 | 1993-12-01 | Glaxo Spa | Heterocyclic compounds |
| NZ291508A (en) | 1994-08-30 | 1999-07-29 | Sankyo Co | Isoxazoles; preparation and medicaments |
| US5484763A (en) | 1995-02-10 | 1996-01-16 | American Cyanamid Company | Substituted benzisoxazole and benzisothiazole herbicidal agents |
| US5554383A (en) | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| US5859042A (en) | 1995-09-27 | 1999-01-12 | Ono Pharmaceutical Co., Ltd. | Five membered heterocyclic compounds |
| GB9617990D0 (en) | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
| TW524667B (en) | 1996-12-05 | 2003-03-21 | Pfizer | Parasiticidal pyrazoles |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| US6500827B2 (en) | 1998-05-08 | 2002-12-31 | Pharmacia & Upjohn Company | Drug combinations |
| US6476078B2 (en) | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
| GB9904786D0 (en) | 1999-03-02 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
| US6828460B2 (en) | 1999-03-22 | 2004-12-07 | Pfizer Inc. | Resorcinol derivatives |
| US6245782B1 (en) | 1999-05-17 | 2001-06-12 | Heartdrug Research L.L.C. | Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors |
| PT1088824E (pt) | 1999-09-30 | 2004-04-30 | Pfizer Prod Inc | Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase |
| EP1391460A1 (en) | 1999-09-30 | 2004-02-25 | Pfizer Products Inc. | Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
| DE19960917A1 (de) | 1999-12-17 | 2001-06-21 | Bayer Ag | Neue 3-Oxo-2,1-benzisoxazol-1(3H)-carboxamide zur Behandlung von ZNS-Erkrankungen |
| IN187170B (enExample) | 2000-01-04 | 2002-02-23 | Sun Pharmaceutical Ind Ltd | |
| US6632417B2 (en) | 2000-03-07 | 2003-10-14 | Chevron U.S.A. Inc. | Process for preparing zeolites |
| JP2001247462A (ja) | 2000-03-07 | 2001-09-11 | Otsuka Pharmaceut Co Ltd | ウレアーゼ阻害剤 |
| EP1136071A3 (en) | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
| GB0012214D0 (en) | 2000-05-19 | 2000-07-12 | Merck Sharp & Dohme | Therapeutic agents |
| JP2002020291A (ja) | 2000-06-30 | 2002-01-23 | Sumitomo Pharmaceut Co Ltd | 認知機能障害の治療剤 |
| TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
| DE10063992A1 (de) | 2000-12-21 | 2002-07-04 | Max Planck Gesellschaft | Tryptophan-Analoga in Proteinen, Peptiden und peptidischen Leitstrukturen |
| US6372919B1 (en) | 2001-01-11 | 2002-04-16 | Dov Pharmaceutical, Inc. | (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent |
| WO2003065970A2 (en) | 2001-02-20 | 2003-08-14 | Royal College Of Surgeons Ie | Treatment of fibromyalgia and related fatigue syndromes using pindolol |
| US20020123490A1 (en) | 2001-03-01 | 2002-09-05 | Pfizer Inc. | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis |
| US20020183306A1 (en) | 2001-05-30 | 2002-12-05 | Pfizer Inc. | Combination treatment for sleep disorders including sleep apnea |
| WO2003000657A1 (en) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| US6603000B2 (en) | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
| US7504395B2 (en) | 2001-07-20 | 2009-03-17 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
| JP4042477B2 (ja) | 2001-12-21 | 2008-02-06 | 日産自動車株式会社 | 車両用運転操作補助装置 |
| US7045543B2 (en) | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
| AU2002364517A1 (en) | 2001-11-30 | 2003-06-17 | Sepracor Inc. | Tramadol analogs and uses thereof |
| KR100423875B1 (ko) | 2001-12-06 | 2004-03-22 | 주식회사 포스코 | 키랄 아민의 제조 방법 |
| TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| JP2003335678A (ja) | 2002-05-17 | 2003-11-25 | Sumitomo Pharmaceut Co Ltd | 神経因性疼痛治療薬 |
| US7576204B2 (en) | 2002-07-31 | 2009-08-18 | Mercian Corporation | Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same |
| US7674482B2 (en) * | 2002-08-27 | 2010-03-09 | Targeted Medical Pharma Inc. | Method and compositions for potentiating pharmaceuticals with amino acid based medical foods |
| AU2003272285A1 (en) | 2002-09-06 | 2004-03-29 | Janssen Pharmaceutica, N.V. | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands |
| JP2006504693A (ja) * | 2002-09-16 | 2006-02-09 | セプラコア インコーポレーテッド | トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミンによるｃｎｓ障害の治療 |
| EP1542961B1 (en) * | 2002-09-16 | 2013-09-11 | Sepracor, Inc. | Trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine for use in treatment of cns disorders |
| US8134029B2 (en) * | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| JP2006504795A (ja) | 2002-10-03 | 2006-02-09 | サイプレス バイオサイエンス， インコーポレイテッド | 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬 |
| AU2004207731B2 (en) | 2003-01-31 | 2009-08-13 | Sanwa Kagaku Kenkyusho Co., Ltd. | Compound inhibiting dipeptidyl peptidase iv |
| WO2004096768A1 (en) | 2003-04-30 | 2004-11-11 | Pfizer Products Inc. | Anti-diabetic agents |
| EP1362864B1 (fr) | 2003-06-30 | 2007-04-25 | Les Laboratoires Servier | Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables |
| KR20060033780A (ko) | 2003-07-07 | 2006-04-19 | 시바 스페셜티 케미칼스 홀딩 인크. | 푸로피롤의 제조방법 |
| US7396940B2 (en) | 2003-10-23 | 2008-07-08 | Hoffmann-La Roche Inc. | Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid |
| PT1420028E (pt) | 2003-11-19 | 2007-05-31 | Servier Lab | Processo de síntese do perindopril e dos seus sais farmacêuticamente aceitáveis. |
| US8304431B2 (en) * | 2003-12-02 | 2012-11-06 | Pharmaneuroboost N.V. | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| PT1691811E (pt) | 2003-12-11 | 2014-10-30 | Sunovion Pharmaceuticals Inc | Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão |
| NZ548212A (en) | 2003-12-29 | 2010-07-30 | Sepracor Inc | Pyrrole and pyrazole DAAO inhibitors |
| ZA200605384B (en) | 2003-12-29 | 2007-10-31 | Sepracor Inc | Benzo[D]isoxazol-3-OL DAAO inhibitors |
| ATE454140T1 (de) | 2004-02-18 | 2010-01-15 | Sepracor Inc | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität |
| CA2557850A1 (en) * | 2004-04-05 | 2005-10-20 | Sepracor Inc. | Methods of treatment using eszopiclone |
| US7465729B2 (en) * | 2004-04-05 | 2008-12-16 | Sepracor Inc. | Methods of treatment of menopause and perimenopause using eszopiclone |
| AP2353A (en) | 2004-05-07 | 2012-02-16 | Warner Lambert Co | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands. |
| EP2261218B1 (en) | 2004-05-26 | 2013-04-03 | Eisai R&D Management Co., Ltd. | Imidazole compound for use as an intermediate in the production of cinnamide compounds |
| US7276631B2 (en) | 2004-07-20 | 2007-10-02 | Bristol-Myers Squibb Company | Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists |
| US20080262071A1 (en) | 2004-09-17 | 2008-10-23 | Timothy Dinan | Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder |
| CN100391945C (zh) | 2005-05-31 | 2008-06-04 | 浙江大学 | 一种s-(-)-吲哚啉-2-羧酸的合成方法 |
| WO2007006003A2 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| CN101257907A (zh) | 2005-07-06 | 2008-09-03 | 塞普拉科公司 | 左旋佐匹克隆和抗抑郁剂的组合 |
| WO2007005940A2 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| EP1904046A4 (en) | 2005-07-06 | 2008-10-01 | Sepracor Inc | COMBINATIONS OF ESZOPICLON AND O-DESMETHYLVENLAFAXINE AND METHOD FOR THE TREATMENT OF MENOPAUSE AND HUMOR FLUCTUATIONS; ANXIETY AND COGNITIVE INTERFERENCE |
| BRPI0615771A2 (pt) | 2005-09-09 | 2011-05-24 | Wyeth Corp | método que compreende administrar a um paciente uma forma de dosagem oral; método para minimizar um efeito colateral adverso associado com a administração de lecozotan a um paciente; método para administrar lecozotan a um paciente; método de tratar doença de alzheimer em um paciente; uso de lecozotan na preparação de um medicamento na forma de dosagem oral; e uso de lecozotan na preparação de um medicamento na forma de dosagem oral para minimizar um efeito colateral adverso associado com a administração de lecozotan a um paciente |
| UA95788C2 (en) | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
| US8053603B2 (en) | 2006-01-06 | 2011-11-08 | Sunovion Pharmaceuticals Inc. | Tetralone-based monoamine reuptake inhibitors |
| KR101294014B1 (ko) | 2006-01-06 | 2013-08-09 | 선오비온 파마슈티컬스 인코포레이티드 | 모노아민 재흡수 저해제로서의 시클로알킬아민 |
| DK2816024T3 (en) | 2006-03-31 | 2017-10-30 | Sunovion Pharmaceuticals Inc | CHIRALE AMINER |
| AU2007254751A1 (en) | 2006-05-31 | 2007-12-13 | Sepracor Inc. | Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide |
| US20080058395A1 (en) | 2006-06-30 | 2008-03-06 | Sepracor Inc. | Fused heterocyclic inhibitors of D-amino acid oxidase |
| US7579370B2 (en) | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| CN1962656A (zh) | 2006-11-29 | 2007-05-16 | 沈阳药科大学 | 吲哚美辛5－氟尿嘧啶甲酯药用化合物及其制剂和制备方法 |
| US20080175903A1 (en) * | 2006-12-01 | 2008-07-24 | Sepracor Inc. | Treatment of anxiety with eszopiclone |
| US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| US20090099248A1 (en) | 2007-01-18 | 2009-04-16 | Sepracor Inc. | Inhibitors of d-amino acid oxidase |
| MX2009012685A (es) | 2007-05-31 | 2009-12-14 | Sepracor Inc | Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina. |
| EP2170310A4 (en) * | 2007-06-29 | 2010-06-23 | Orchid Chemicals & Pharm Ltd | FAST-DISSOLVING COMPOSITIONS OF MEMANTINE HYDROCHLORIDE |
| WO2010017418A1 (en) | 2008-08-07 | 2010-02-11 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| EP2429514A1 (en) | 2009-05-13 | 2012-03-21 | Sunovion Pharmaceuticals Inc. | Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof |
-
2006
- 2006-07-06 WO PCT/US2006/026361 patent/WO2007006003A2/en not_active Ceased
- 2006-07-06 CA CA002614282A patent/CA2614282A1/en not_active Abandoned
- 2006-07-06 JP JP2008520398A patent/JP2009500425A/ja active Pending
- 2006-07-06 AU AU2006264317A patent/AU2006264317B2/en not_active Ceased
- 2006-07-06 CN CNA2006800326226A patent/CN101553217A/zh active Pending
- 2006-07-06 EP EP06786496.7A patent/EP1904066B1/en not_active Expired - Lifetime
- 2006-07-06 US US11/994,644 patent/US20080293726A1/en not_active Abandoned
- 2006-07-06 MX MX2008000250A patent/MX2008000250A/es active IP Right Grant
- 2006-07-06 EP EP12152928.3A patent/EP2455075B1/en not_active Expired - Lifetime
- 2006-07-06 CA CA2957667A patent/CA2957667A1/en not_active Abandoned
-
2012
- 2012-01-25 US US13/358,155 patent/US8329950B2/en not_active Expired - Fee Related
- 2012-11-09 US US13/673,076 patent/US20130065904A1/en not_active Abandoned
-
2014
- 2014-06-27 US US14/317,754 patent/US20140315910A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10562878B2 (en) | Cycloalkylamines as monoamine reuptake inhibitors | |
| EP1192122B1 (fr) | Derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant | |
| JP4205182B2 (ja) | 医薬有効物質としてのジメチル−（３−アリール− ブト−３− エニル）−アミノ化合物 | |
| AU2006335174B2 (en) | Tetralone-based monoamine reuptake inhibitors | |
| JP2023540017A5 (enExample) | ||
| JP2009500420A5 (enExample) | ||
| JP2003506426A5 (enExample) | ||
| EP2032534B1 (en) | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions | |
| US7217729B2 (en) | Substituted indoles, process for the production thereof and use thereof for combatting pain | |
| WO2016101898A1 (zh) | 3-[(苯并[d][1，3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用 | |
| TW200304815A (en) | NK1 antagonists | |
| JP2005511570A (ja) | 置換ベンゾ［ｂ］アゼピン−２−オン化合物 | |
| JP2005511567A (ja) | 置換１ｈ−キノリン−２−オン化合物 | |
| AU2002239572B2 (en) | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines | |
| WO2015131814A2 (zh) | [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用 | |
| JP2002020287A (ja) | 窒素含有複素環式化合物のフルオロアルコキシベンジルアミノ誘導体の医薬的使用 | |
| EA009417B1 (ru) | Производные 4-(2-фенилоксифенил)пиперидина или -1,2,3,6-тетрагидропиридина в качестве ингибиторов обратного захвата серотонина | |
| JP2026501636A (ja) | ２－フェニル－２－アミノシクロヘキサン－１－オン誘導体の合成 | |
| AU2008200875A1 (en) | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines | |
| NZ522391A (en) | Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P antagonists | |
| HK1130053B (en) | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions | |
| SK162595A3 (en) | N-substituted azaheterocyclic carboxylic acids and esters thereof |